Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis
Ann Am Thorac Soc
.
2017 Sep;14(9):1383-1384.
doi: 10.1513/AnnalsATS.201706-423ED.
Author
Brett Ley
1
Affiliation
1
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
PMID:
28862501
DOI:
10.1513/AnnalsATS.201706-423ED
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Idiopathic Pulmonary Fibrosis*
Respiratory System Agents*
Tidal Volume
Vital Capacity
Substances
Respiratory System Agents